Skip to content


Brexafemme (ibrexafungerp) is a small molecule pharmaceutical. Ibrexafungerp was first approved as Brexafemme on 2021-06-01. It is used to treat vulvovaginal candidiasis in the USA. Brexafemme's patents are valid until 2035-01-19 (FDA).
Trade Name Brexafemme
Common Name Ibrexafungerp
Indication vulvovaginal candidiasis
Drug Class Antifungal
Get full access now